טוען...
Metformin and Prostate Cancer: Benefit for Development of Castration-resistant Disease and Prostate Cancer Mortality
BACKGROUND: In vitro data and early clinical results suggest that metformin has desirable antineoplastic effects and has a theoretical benefit on castration-resistant prostate cancer (CRPC). OBJECTIVE: To determine whether the use of metformin would be associated with improved clinical outcomes and...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4034673/ https://ncbi.nlm.nih.gov/pubmed/23287698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2012.12.004 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|